



CHP+

Child Health Plan *Plus*

Department of Health Care Policy and Financing
Benefits & Services Division
1570 Grant Street
Denver, CO 80203

CHP+ Billing Guidance for Specialty Drugs

Effective July 1, 2021 for services meeting the criteria of a select list of Specialty Drugs, as defined and listed in this CHP+ billing guidance, which may be accessed through Colorado Department of Health Care Policy and Finance’s website, that would have otherwise been compensated through the EAPG methodology, providers and facilities must submit a request for authorization to the Member’s Managed Care Organization prior to administration of the Specialty Drug.

If the requested prior authorization is approved and the covered service(s) are administered, then the Managed Care Organization must obtain an invoice showing the Facility’s actual acquisition cost of the drug before rendering payment to the facility or the provider(s). Additionally, the Managed Care Organization must submit this invoice and prior authorization documentation to the Department within 30 calendar days of releasing payment(s).

The Department will pay the Managed Care Organization 72% of the rendering Facility’s actual acquisition cost of the drug, as evidenced by their net invoice cost. The payment terms for these covered services between the Managed Care Organization and their contracted providers and facilities are beyond the Department’s purview and therefore immaterial to the payment terms between the Department and the Managed Care Organization.

The payment methodology described herein is supplemental to, and in accordance with, the Colorado CHP+ Program capitation payment model. The Department’s list of Specialty Drugs is posted in [Appendix Z](#), which the CHP+ program shall follow from the effective date above. Drugs included on the Specialty Drug list may be updated by the Department at any time and all changes will be posted in [Appendix Z](#).

Version Date October 11, 2021

